Abstract
Alzheimer's disease (AD) is characterized by the deposition of amyloid-β (Aβ) protein in the brain. Immunization studies have demonstrated that anti-Aβ antibodies reduce Aβ deposition and improve clinical symptoms seen in AD. However, conventional antibody-based therapies risk an inflammatory response that can result in meningoencephalitis and cerebral hemorrhage. Here we report on the development of human-based single chain variable domain antibody fragments (scFvs) directed against the Aβ 25-35 region as potential therapeutics for AD that do not risk an inflammatory response. The 25-35 region of Aβ represents a promising therapeutic target since it promotes aggregation and is highly toxic. Two scFvs with differing affinities for Aβ were studied, and both inhibited aggregation of Aβ42 as determined by thioflavin T binding assay and atomic force microscopy analysis and blocked Aβ-induced toxicity toward human neuroblastoma SH-SY5Y cells as determined by MTT and LDH release assays. These results provide additional evidence that scFvs against Aβ provide an attractive alternative to more conventional antibody-based therapeutics for controlling aggregation and toxicity of Aβ.
Original language | English (US) |
---|---|
Pages (from-to) | 11532-11539 |
Number of pages | 8 |
Journal | Biochemistry |
Volume | 45 |
Issue number | 38 |
DOIs | |
State | Published - Sep 26 2006 |
ASJC Scopus subject areas
- Biochemistry